首页> 美国卫生研究院文献>Gut >Octreotide induced prolongation of colonic transit increases faecal anaerobic bacteria bile acid metabolising enzymes and serum deoxycholic acid in patients with acromegaly
【2h】

Octreotide induced prolongation of colonic transit increases faecal anaerobic bacteria bile acid metabolising enzymes and serum deoxycholic acid in patients with acromegaly

机译:奥曲肽诱导的结肠转运延长增加肢端肥大症患者的粪便厌氧菌胆汁酸代谢酶和血清脱氧胆酸

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Background: Acromegalic patients have slow colonic transit, increased rates of deoxycholic acid formation, and an increased prevalence of cholesterol gall stones, especially during long term octreotide treatment. However, the effects of this prolonged large bowel transit time on the numbers of faecal anaerobes and the activities of the enzyme systems which biotransform conjugated cholic acid into unconjugated deoxycholic acid (cholylglycine hydrolase and 7α-dehydroxylase) are unknown.>Methods: Therefore, in 10 non-acromegalic controls, 11 acromegalic patients not treated with octreotide, and 11 acromegalics on long term (8–48 months) octreotide (100–200 μg three times daily subcutaneously), we measured large bowel transit time and, in freshly voided faeces, the activities of the two bile acid metabolising enzymes, and related the results to the proportion of deoxycholic acid in fasting serum. Moreover, in patients with acromegaly, we measured quantitative bacteriology in faeces.>Results: Mean large bowel transit time in acromegalics not treated with octreotide (35 (SEM 6.5) hours) was 66% longer than that in non-acromegalic controls (21 (3.1) hours; NS) and became further prolonged during octreotide treatment (48 (6.6) hours; p<0.001). These octreotide induced changes in transit were associated, in acromegalic patients, with more total (15.0 (2.5) v 6.3 (1.3)×109 colony forming units (cfu)/g; p<0.05) and Gram positive (6.3 (2.3) v 3.2 (1.0)×109 cfu/g; p<0.05) faecal anaerobes. Mean faecal cholylglycine hydrolase activity in the long term octreotide group (22.0 (6.0)×10−2 U/mg protein) was 138% greater than that in non-acromegalic controls (12.0 (6.0)×10−2; p<0.01). Similarly, mean 7α-dehydroxylase activity in octreotide treated acromegalics (11.1 (1.18)×10−4 U/mg protein) was 78% greater than that in patients not receiving long term octreotide (6.3 (0.5)×10−4; p<0.001). The mean proportion of deoxycholic acid in fasting serum also increased from 18.0 (2.88)% in the untreated group to 29.6 (2.3)% during long term octreotide (p<0.05). There were significant linear relationships between large bowel transit time and: (i) faecal 7α-dehydroxylase activity; and (ii) the proportion of deoxycholic acid in fasting serum and between 7α-dehydroxylase activity and the proportion of deoxycholic acid in serum.>Summary/interpretation: These data suggest that increased deoxycholic acid formation seen in acromegalics during octreotide treatment is due not only to the greater numbers of faecal anaerobes but also to increased activity of the rate limiting enzyme pathway (7α-dehydroxylation) converting cholic acid to deoxycholic acid.
机译:>背景:肢端肥大症患者的结肠运输缓慢,脱氧胆酸形成的速率增加,胆固醇胆结石的患病率增加,尤其是在长期奥曲肽治疗期间。但是,这种延长的大肠通行时间对粪便厌氧菌数量的影响以及将共轭胆酸生物转化为非共轭脱氧胆酸的酶系统(胆固醇甘氨酸水解酶和7α-脱羟化酶)的活性尚不清楚。>方法:< / strong>因此,在10个非肢端肥大对照中,有11例未经奥曲肽治疗的肢端肥大症患者,以及11例长期(8-48个月)奥曲肽(每天皮下注射3次,每次100-200μg)的肢端肥大症,我们测量了大肠的转运时间以及在新鲜排泄的粪便中,两种胆汁酸代谢酶的活性,并将结果与​​空腹血清中脱氧胆酸的比例相关。此外,在肢端肥大症患者中,我们测量了粪便中的定量细菌学。>结果:未经奥曲肽治疗的肢端肥大症(35(SEM 6.5)小时)的平均大肠通行时间比未使用奥曲肽治疗的肢体大肠时间长66%。 -肢端肥大对照(21(3.1)小时; NS),并在奥曲肽治疗期间进一步延长(48(6.6)小时; p <0.001)。在肢端肥大症患者中,这些奥曲肽诱导的过境变化与总菌落形成单位(cfu)/ g(15.0(2.5)v 6.3(1.3)×10 9 )的总含量更高(p <0.05)和粪便厌氧菌阳性(6.3(2.3)v 3.2(1.0)×10 9 cfu / g; p <0.05)长期奥曲肽组(22.0(6.0)×10 −2 U / mg蛋白)的粪便胆碱甘氨酸水解酶平均活性比非肢端肥大对照组(12.0(6.0)×10)高138%。 -2 ; p <0.01)。同样,奥曲肽治疗的肢端肥大症(11.1(1.18)×10 −4 U / mg蛋白)的平均7α-脱羟酶活性比未接受长期奥曲肽的患者的平均7α-脱羟酶活性高(6.3(0.5) ×10 −4 ; p <0.001)。空腹血清中脱氧胆酸的平均比例也从未治疗组的18.0(2.88)%增加到长期奥曲肽治疗期间的29.6(2.3)%(p <0.05)。大肠运输时间与以下情况之间存在显着的线性关系:(i)粪便7α-脱羟基酶活性; (ii)空腹血清中脱氧胆酸的比例以及7α-脱羟化酶活性与血清中脱氧胆酸的比例之间。>摘要/解释:这些数据表明,肢端肥大症患者体内脱氧胆酸形成的增加奥曲肽治疗不仅是由于粪便厌氧菌数量增加,而且还因为速率限制酶途径(7α-脱羟基化)将胆酸转化为脱氧胆酸的活性增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号